NCT06555133 - Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2029

Conditions

Colorectal Carcinoma Metastatic in the Liver

Interventions

COMBINATION_PRODUCT

yttrium-90 radioembolization

yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.

Trial Locations (1)

02903

RECRUITING

Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals Providence, Rhode Island, United States, 02903 Contact:, Providence